US5206268A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Medicaments
Assignee: SmithKline Beecham Corp
•
Filing: 1989-08-15
•
Granted: 1993-04-27
•
Expires: 2009-08-15
Abstract
Abstract A method for treating or preventing a Pneumocystis carinii infection in a mammal by administering a certain naphthoquinone compound or physiologically acceptable salts thereof.
Inventors
- 👤 Victoria S. Latter
- 👤 Winston E. Gutteridge
- 👤 Alan T. Hudson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 02:31
CPC Classifications
C; C07; C07C; C07C229/00; C07C229/52; C07C229/54; C07C229/60; A; A61; A61K; A61K31/00; A61K31/12; C07C217/00; C07C217/02; C07C217/04; C07C217/06; C07C217/12; C07C225/00; C07C225/24; C07C225/26; C07C225/30; C07C46/00; C07C50/00; C07C50/24; C07C50/26; C07C50/32; C07C69/00; C07C69/013; C07C69/017; C07C69/96; C07C2601/00; C07C2601/12; C07C2601/14; C07C2602/00; C07C2602/02; C07C2602/04; C07C2602/10; C07C2602/14; C07C2602/26; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
21 words
A method of treating malaria in a mammal comprising administering to said mammal an effective antimalarial amount of a compound 2-[trans-4-(4-chlorophenyl)cyclohexyl]-1,3,4triacetoxynaphthalene.
Claim 2
Independent Claim
21 words
A method of treating malaria in a mammal comprising administering to said mammal an effective antimalarial amount of a compound 2-[trans-4-(4-chlorophenyl)cyclohexyl]-1,3,4triacetoxynaphthalene.
Claim 3
Dependent Claim
27 words
A pharmaceutical formulation in a form for nasal administration or pulmonary administration comprising an effective antimalaria amount of the compound 2-[trans-4-(4-chlorophenyl)cyclohexyl]-1,3,4triacetoxynaphthalene and a pharmaceutically acceptable carrier therefor.
Claim 4
Dependent Claim
27 words
A pharmaceutical formulation in a form for nasal administration or pulmonary administration comprising an effective antimalaria amount of the compound 2-[trans-4-(4-chlorophenyl)cyclohexyl]-1,3,4triacetoxynaphthalene and a pharmaceutically acceptable carrier therefor.
References Cited (Backward Citations)
US2553648A
Cited
US3347742A
Cited
US3367830A
Cited
GB1553424A
Cited
EP0002228B1
Cited
EP0077551A2
Cited
EP0077550B1
Cited
EP0123239A2
Cited
EP0123238A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-04-26 | 1996-10-26 | 1997-04-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-04-26 | 2000-10-26 | 2001-04-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-04-26 | 2004-10-26 | 2005-04-27 | $7700.00 | Window Closed / Lapsed |